

Boehringer Ingelheim strengthens fight against NCDs

01 November 2019 | News

Non-communicable diseases make up 85 per cent of Boehringer Ingelheim's medicines portfolio



Boehringer Ingelheim, one of the world's leading pharmaceutical companies, has announced its partnership with The Defeat-NCD Partnership, a public-private partnership anchored in the United Nations system.

The aim of this collaboration is to help low-resource countries tackle the premature death, sickness, disability, and associated social and economic impacts from non-communicable diseases. The collaboration was officially announced during the World Health Summit 2019 in Berlin, Germany.

The Defeat-NCD Partnership and Boehringer Ingelheim share a vision of driving access to healthcare in low-resource countries. The Partnership will contribute concretely by helping governments to strengthen key national institutions, scaling up community based health services, as well as expanding the accessible range of medicines and healthcare solutions.

Boehringer Ingelheim's medicines portfolio has one of the strongest medical research and development pipelines in areas of unmet medical needs, with non-communicable diseases making up 85 per cent.

Through the company's renewed "Access to Healthcare" strategy, based on the three strategic pillars "Availability", "Innovative Solutions" and "Sustainable Models", the company is exploring and evaluating a differentiated holistic approach for broadening healthcare access for underserved communities and countries.

In the next decade, Boehringer Ingelheim aims to extend access to healthcare best practices to many current and new markets, within the framework of the 2030 Agenda for Sustainable Development adopted by the United Nations.